Bayer Aktiengesellschaft (BUD:BAYER)

Hungary flag Hungary · Delayed Price · Currency is HUF
15,800
-102 (-0.64%)
At close: Feb 27, 2026
Market Cap15.55T +84.3%
Revenue (ttm)17.88T -1.9%
Net Income-77.21B
EPS-78.59
Shares Outn/a
PE Ration/a
Forward PE8.36
Dividend44.63 (0.27%)
Ex-Dividend DateApr 28, 2025
Volume10
Average Volume227
Open15,800
Previous Close15,902
Day's Range15,800 - 15,800
52-Week Range7,500 - 18,700
Betan/a
RSI45.27
Earnings DateMar 4, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Industry Chemicals and Allied Products
Founded 1863
Employees 88,502
Stock Exchange Budapest Stock Exchange
Ticker Symbol BAYER
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial numbers in EUR Financial Statements

News

Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy

Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy

1 day ago - GuruFocus

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef...

1 day ago - Business Wire

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Tril...

1 day ago - Wallstreet:Online

Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial

Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial

2 days ago - GuruFocus

Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer

Bayer Xofigo + Pfizer/Astellas Xtandi improved survival in mCRPC with bone metastases. Read more here.

2 days ago - Seeking Alpha

Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.

3 days ago - Business Wire

Bayer’s XOFIGO (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Final results from the pivotal investigational Phase III PEACE-3 trial demonstrate that first-line treatment with XOFIGO (radium-223 dichloride) in combination with enzalutamide, an androgen receptor ...

3 days ago - Wallstreet:Online

Lawyers for US cancer sufferers challenge Bayer’s $7.25bn Roundup settlement deal

Proposed settlement would pay users of glyphosate-based weedkiller who have non-Hodgkin lymphoma $10,000 to $165,000 A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to interve...

3 days ago - The Guardian

Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows

Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25 ...

3 days ago - Reuters

Bayer Sues J&J Over 51% Claim

Bayer Sues J&J Over 51% Claim

5 days ago - GuruFocus

Bayer sues Johnson & Johnson over prostate cancer drug claims

Bayer (BAYRY) sued Johnson & Johnson (JNJ) on Monday, alleging a false advertising campaign for its prostate cancer drug Erleada.

5 days ago - Seeking Alpha

Bayer Sues J&J Over Prostate Cancer Treatment Promotion Dispute

(RTTNews) - German pharmaceutical and life sciences major Bayer AG (BAYRY.PK, BAYZF.PK) announced that it has filed false advertising suit against Johnson & Johnson or J&J (JNJ) and Janssen Biotech, I...

5 days ago - Nasdaq

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.

6 days ago - Reuters

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...

6 days ago - Business Wire

Bayer Alleges J&J’s Claims Regarding NUBEQA are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of New York. The suit follows J&J’s...

6 days ago - Wallstreet:Online

Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season

ST. LOUIS--(BUSINESS WIRE)--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginni...

6 days ago - Business Wire

Voyageur Pharmaceuticals Announces Collaboration with Bayer

Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...

6 days ago - TheNewswire

Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms

A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks ...

9 days ago - Fast Company

Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer

Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...

10 days ago - Benzinga

Bayer: glyphosate shortages not expected outside the US after executive order

The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, ad...

10 days ago - Reuters

Trump Invokes Defense Act For Monsanto Chemicals: Bayer, Agribusiness ETFs In Focus On New Critical Mineral Status For Phosphorus

In a major move to solidify the America First industrial strategy, President Donald Trump signed an executive order on Feb. 18, mobilizing the Defense Production Act (DPA) to secure the domestic suppl...

10 days ago - Benzinga

Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?

Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awai...

10 days ago - Reuters

Bayer Falls 8.4% On $7.25 Billion Plan

Bayer Falls 8.4% On $7.25 Billion Plan

11 days ago - GuruFocus